NTS is developing a pipeline of disease-modifying molecules designed to address the acute and post-injury deficits that can persist for weeks to years following a brain injury.
NTS-104 is the pro-drug of NTS-105, which is a novel neurosteroid demonstrating a unique pharmacologic profile including anti-inflammatory and cytoprotective actions. NTS-104 has shown efficacy in multiple pre-clinical models of acute ischemic stroke and TBI. NTS-105 readily enters the brain and potently modulates key target receptors, protecting cells from inflammation, ischemia, and hypoxia.
Comments are closed.